Clinical Trial Update: Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating ticagrelor-based de-escalation of dual antiplatelet therapy after coronary artery bypass grafting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris
• Coronary Artery Disease
• Myocardial Infarction
• Myocardial Ischemia

Drugs mentioned

• BRILINTA (ticagrelor)

Snippet

Sponsor: China National Center for Cardiovascular Diseases | Conditions: Coronary Artery Disease, Coronary Artery Bypass Grafting | Phase 4 | Status: COMPLETED